Answers are grounded in this paper and cite their sources.
Multicenter phase II trial demonstrates safety and tumor response with perioperative pembrolizumab in resectable HPV-unrelated head and neck cancer, suggesting reduced relapse rates.
Among patients with locally advanced, HPV-unrelated HNSCC, pembrolizumab was safe, and any pathologic response was observed in 44% of patients with 0% pathologic complete responses. The 1-year relapse rate in patients with high-risk pathology was lower than historical.
No takes yet. Share an insight, caveat, or question.
Uppaluri et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: